Korean Market
FTC
YUNGJIN PHARM
★

YUNGJIN PHARM's Annual Corporate Group Disclosure – Financial Structure and Largest Shareholder Stake at 52.45%

 
EXCH
YUNGJIN PHARM
★

YUNGJIN PHARM. Corporate Governance Report: Efforts to improve governance through bylaw amendments and independent director reinforcement, but absence of dividends and shareholder return policy remains disappointing

 
PERI
YUNGJIN PHARM
★★

Yungjin Pharm Q1 Swings to Operating Loss, Cash Plunges; Lawsuit Settlement Removes Uncertainty

 
EXCH
YUNGJIN PHARM
★★★

Yungjin Pharmaceutical Q1 2026 Preliminary: Slight Revenue Decline, Operating Loss Swing